Skip to main content

In this sixth episode, Cohen discussed aligning patient expectations with the goals of antiamyloid antibody treatment, emphasizing disease slowing, eligibility factors, and real-world satisfaction data. Supported by Eli Lilly.:

Source: Neurology Read More